It is involved in the alternative splicing of the apoptosis regulatory gene FAS, overexpressed in breast, ovarian, and prostate cancers, and contributes to tumor drug resistance.26, 27, 28, 29. This evidence concerns the gene FAS and prostate carcinoma.